Turnstone Biologics Announces US FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers – Watertown Public Opinion
|
Turnstone Biologics Announces US FDA Acceptance of IND for Immunotherapy Targeting HPV Positive Cancers
Watertown Public Opinion Turnstone's MG1 virus is the first immunotherapy engineered to function as both a selective tumor-destroying oncolytic virus and an immune stimulating T cell vaccine. MG1 directly attacks cancer cells and modifies the microenvironment to make tumor … |
